


Gemcabene

Cat. No.:	HY-109567		
CAS No.:	183293-82-5		
Molecular Formula:	C ₁₆ H ₃₀ O ₅		
Molecular Weight:	302.41		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (413.35 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.3068 mL	16.5338 mL	33.0677 mL
	5 mM	0.6614 mL	3.3068 mL	6.6135 mL
	10 mM	0.3307 mL	1.6534 mL	3.3068 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: **10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline**
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution
- Add each solvent one by one: **10% DMSO >> 90% (20% SBE-β-CD in saline)**
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution
- Add each solvent one by one: **10% DMSO >> 90% corn oil**
Solubility: ≥ 2.08 mg/mL (6.88 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity^{[1][2][3]}.

In Vitro

Gemcabene calcium (PD-72953 calcium) significantly downregulates hepatic mRNA markers of inflammation (TNF-α,

MCP-1, MIP-1 β , CCR5, CCR2, NF- κ B), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2)^[3].

REFERENCES

- [1]. Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22.
- [2]. Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.
- [3]. Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA